We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Administration options for pegfilgrastim prophylaxis: patient and physician preferences from a cross-sectional survey.
- Authors
Hauber, A. Brett; Mange, Brennan; Price, Mark A.; Wolin, Daniel; Bensink, Mark; Kaye, James A.; Chandler, David
- Abstract
<bold>Objective: </bold>Although clinical guidelines recommend administration of pegfilgrastim 1-4 days after a myelosuppressive chemotherapy cycle to decrease the incidence of febrile neutropenia (FN), some physicians administer pegfilgrastim on the same day as chemotherapy administration. A novel on-body injector (OBI) that automatically delivers pegfilgrastim the day after chemotherapy is also available. Our objective was to estimate patient and physician preferences among the pegfilgrastim administration options.<bold>Methods: </bold>We conducted a cross-sectional survey of patients receiving pegfilgrastim and physicians prescribing pegfilgrastim. Respondents' preferences for pegfilgrastim administration options were elicited using direct elicitation; the relative importance of features associated with the options was estimated in a point-allocation exercise. Physicians considered two hypothetical patient profiles when completing the exercises.<bold>Results: </bold>The samples included 200 patients and 200 physicians. Patients generally preferred the administration option with which they had experience. Among patients, 48.5% with previous in-clinic injections 24 hours after chemotherapy preferred this option; 56.8% with previous OBI administration preferred this option. For a clinically compromised patient, 37.5% of physicians preferred an in-clinic injection option; 49.5% preferred the OBI. For a less compromised patient, 55.5% preferred an in-clinic injection option; 28.0% preferred the OBI. Avoiding the need to return to the clinic was chosen most often as the most important treatment feature for patients and physicians.<bold>Conclusions: </bold>Patients and physicians identified that returning clinic visits for pegfilgrastim administration may be burdensome. A potential solution to mitigate this burden is the OBI, which allows adherence to the labeled use of pegfilgrastim without return visits to the clinic.
- Subjects
FILGRASTIM; PREVENTIVE medicine; CHEMOTHERAPY complications; PHYSIOLOGICAL effects of chemotherapy; NEUTROPENIA; DIAGNOSIS; THERAPEUTICS; PHYSICIAN-patient relations; POLYETHYLENE glycol; CROSS-sectional method; ETHICS
- Publication
Supportive Care in Cancer, 2018, Vol 26, Issue 1, p251
- ISSN
0941-4355
- Publication type
journal article
- DOI
10.1007/s00520-017-3841-2